Abstract:Purpose: The clinical use of paclitaxel (PTX) in cancer treatment is limited by its poor water solubility, significant toxicity, and adverse effects. This study aimed to propose a straightforward and efficient approach to enhance PTX loading and stability, thereby offering insights for targeted therapy against tumors. Patients and methods: We synthesized a paclitaxel palmitate (PTX-PA) prodrug by conjugating palmitic acid (PA) to PTX and encapsulating it into liposomal vehicles using a nano delivery system. Subsequently, we investigated the in vitro and in vivo performance as well as the underlying mechanisms of PTX-PA liposomes (PTX-PA-L). Results: PTX had a remarkable antitumor effect in vivo and significantly decreased the myelosuppressive toxicity of PTX. Moreover, the introduction of PA increased the lipid solubility of PTX, forming a phospholipid bilayer as a membrane stabilizer, prolonging the circulation time of the drug and indirectly increasing the accumulation of liposomes at the tumor site. Our in vivo imaging experiments demonstrated that PTX-PA-L labeled with DiR has greater stability in vivo than blank liposomes and that PTX-PA-L can target drugs to the tumor site and efficiently release PTX to exert antitumor effects. In a mouse model, the concentration of PTX at the tumor site in the PTX-PA-L group was approximately twofold greater than that of Taxol. However, in a nude mouse model, the concentration of PTX at the tumor site in the PTX-PA-L group was only approximately 0.8-fold greater than that of Taxol. Furthermore, the originally observed favorable pharmacodynamics in normal mice were reversed following immunosuppression. This may be caused by differences in esterase distribution and immunity. Conclusion: This prodrug technology combined with liposomes is a simple and effective therapeutic strategy with promising developmental prospects in tumor-targeted therapy owing to its ability to convert PTX into a long-circulating nano drug with low toxicity, high pharmacodynamics, and good stability in vivo.

Study on in Vitro Cytotoxicity and in Vivo Antitumor Effect of Liposomes Containing Topotecan Hydrochloride

In Vitro and In Vivo Studies of Different Liposomes Containing Topotecan

Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer

[Inhibition Effect of Topotecan on Human Myelodysplastic Syndrome Cells in Vitro and in Vivo].

Modulating Tumour Vascular Normalisation Using Triptolide-Loaded NGR-functionalized Liposomes for Enhanced Cancer Radiotherapy

Preparation of thermosensitive liposomes containing paclitaxel and their anticancer effect

Preparation and Biodistribution of Topotecan Liposomes

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

Antitumor Effects of Docetaxel in Truncated Basic Fibroblast Growth Factor- Functionalized Liposomes Delivered by d-α-tocopheryl Polyethylene Glycol 2000 Succinate

A Continued Study on the Stealth Liposomal Topotecan Plus Amlodipine: in Vitro and in Vivo Characterization in Non-Resistant Solid Tumors

Lactone Stabilized by Crosslinked Cyclodextrin Metal-Organic Frameworks to Improve Local Bioavailability of Topotecan in Lung Cancer

Enhanced in Vitro and in Vivo Therapeutic Efficacy of Codrug-Loaded Nanoparticles Against Liver Cancer

Preparation of etoposide liposomes for enhancing antitumor efficacy on small cell lung cancer and reducing hematotoxicity of drugs

Exploration of the inhibition action of TPGS on tumor cells and its combined use with chemotherapy drugs

A lyophilized sterically stabilized liposome-containing docetaxel: in vitro and in vivo evaluation

Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy

Enhanced in vivo Stability and Antitumor Efficacy of PEGylated Liposomes of Paclitaxel Palmitate Prodrug

PTD Modified Paclitaxel Anti-Resistant Liposomes for Treatment of Drug-Resistant Non-Small Cell Lung Cancer

Enhancement of Radiotherapy Efficacy by Pleiotropic Liposomes Encapsulated Paclitaxel and Perfluorotributylamine.

Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel

Antitumor efficiency of D-alpha-tocopheryl polyethylene glycol 1000 succinate-b-poly(epsilon-caprolactone-ran-lactide) nanoparticle-based delivery of docetaxel in mice bearing cervical cancer.